Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report

Interstitial pneumonitis is a rare but potentially fatal side effect occurring from 2 weeks to 16 weeks after the initiation of treatment with pegylated interferon alpha and ribavirin for chronic hepatitis C. Herein, we present a 68-year-old man with chronic hepatitis C virus infection who developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Atug, Ozlen, Akin, Hakan, Alahdab, Yesim Ozen, Ceyhan, Berrin, Tozun, Nurdan, Ozdogan, Osman
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827138/
https://www.ncbi.nlm.nih.gov/pubmed/20181162
http://dx.doi.org/10.1186/1757-1626-2-6464
Descripción
Sumario:Interstitial pneumonitis is a rare but potentially fatal side effect occurring from 2 weeks to 16 weeks after the initiation of treatment with pegylated interferon alpha and ribavirin for chronic hepatitis C. Herein, we present a 68-year-old man with chronic hepatitis C virus infection who developed interstitial pneumonitis association with pegylated interferon after 36 weeks initiation of pegylated interferon-alpha and ribavirin therapy. He did not recover after discontinuation of pegylated interferon/ribavirin and improved by steroid therapy.

Ejemplares similares